Orphan designation: Recombinant human heparan-N-sulfatase Treatment of mucopolysaccharidosis type IIIA (Sanfilippo A syndrome), 12/01/2024 Positive
Overview
- Overview
This medicine was designated as an orphan medicine for the treatment of Mucopolysaccharidosis type IIIA (Sanfilippo A syndrome) on 12 January 2024. - Orphan designation does not mean the medicine is available or authorised for use.
- All medicines, including designated orphan medicines, must be authorised before they can be marketed and made available to patients in the EU.
- EU register of orphan medicines
The list of medicines that have received an orphan designation in the EU is available on the European Commission's website: